Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Deribit BTC IV implied volatility rises to 52%

Deribit BTC IV implied volatility rises to 52%

Bitget2024/06/06 04:33

Deribit's Head of Asia Pacific Business, Lin Chen, posted on platform X saying: "The current BTC's IV implied volatility clearly jumped to 52% on June 8th, surpassing the IV data at the end of June. It is clear that the market is buying options to hedge/bet on the U.S. non-farm employment data to be released at 8:30 pm on June 7th. If the data is less than expected, BTC may likely hit a new high; I see this scenario possibly being that after hitting a new high, next Thursday's FOMC meeting will have Fed dovishness controlling everyone's expectations and then prices retreating."

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment

According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.

智通财经•2026/11/06 08:27

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56

Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.

After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.

智通财经•2026/11/06 07:53